SCHEMBL408948

SCHEMBL408948

CC(=N)NC(=N)N(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL471123 0.83 LMNA (0.30)
SCHEMBL23170573 0.77
SCHEMBL16791185 0.77 ALDH1A1 (0.31)
SCHEMBL18557544 0.77
SCHEMBL13206000 0.73
Metformin SCHEMBL1766280 0.73 LMNA (0.36)
Metformin SCHEMBL8944 0.73
SCHEMBL12563236 0.73
SCHEMBL16791181 0.73 ALDH1A1 (0.30)
SCHEMBL3055662 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180214396-A1 COMPOSITION FOR TREATING DIABETES MELLITUS KATO YASUMASA (JP) 2018-08-02 US disclosed
US-20180214396-A1 COMPOSITION FOR TREATING DIABETES MELLITUS KATO YASUMASA (JP) 2018-08-02 US disclosed
US-9862693-B2 Compounds and methods of treating cancer THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2018-01-09 US disclosed
US-20170327455-A1 Omefibrates for Treating Dyslipidemia and Cardiovascular Disease JIVA PHARMA, INC. (US) 2017-11-16 US disclosed
US-20170196890-A1 TGR5 AGONIST COMPLEXES FOR TREATING DIABETES AND CANCER CITY OF HOPE 2017-07-13 US disclosed
US-20170157069-A1 COMPOSITION USING METFORMIN FOR PREVENTING OR TREATING IMMUNE DISEASES INCLUDING LUPUS Catholic University Industry Academic Cooperation Foundation (KR) 2017-06-08 US disclosed
US-9371276-B1 Compositions and methods for the treatment of hyperglycemia and metabolic syndrome ALAPATI MOHAN MURALI (IN) 2016-06-21 US disclosed
US-20160101071-A1 COMBINATION CANCER TREATMENT WISCONSIN ALUMNI RESEARCH FOUNDATION 2016-04-14 US disclosed
US-20150344402-A1 Omefibrates for Treating Dyslipidemia and Cardiovascular Disease JIVA PHARMA, INC. (US) 2015-12-03 US disclosed
US-9174931-B2 Compositions for the treatment of diabetes and pre-diabetes CELLIX BIO PRIVATE LIMITED (IN) 2015-11-03 US disclosed
US-20140018371-A1 Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto ARENA PHARMACEUTICALS, INC. (US) 2014-01-16 US disclosed
US-8581001-B2 Metformin-cysteine prodrug CODMAN & SHURTLEFF (US) 2013-11-12 US disclosed
US-8461331-B2 Method for the production of 3,6-dihydro-L, 3, 5-triazine derivatives from metformin and paraldehyde derivatives POXEL SAS (FR) 2013-06-11 US disclosed
US-20130023494-A1 MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. (US) 2013-01-24 US disclosed
US-20120135952-A1 BUTYRIC ACID SALT OF N,N-DIMETHYL IMIDOCARBON IMIDIC DIAMIDE, METHOD OF PREPARING SAME, AND PHARMACEUTICAL COMPOSITIONS AND COMBINATIONS CONTAINING SAME HANALL BIOPHARMA CO., LTD. (KR) 2012-05-31 US disclosed
US-20120065176-A1 TREATMENT OF MUSCLE DISEASE CHARACTERIZED BY INSULIN RESISTANCE THE UNIVERSITY OF OTTAWA (CA) 2012-03-15 US disclosed
US-20120016121-A1 Process for the separation of enantiomers of 3,6-dihydro-1,3,5-triazine derivatives MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2012-01-19 US disclosed
US-20110257432-A1 Metformin-Cysteine Prodrug CODMAN & SHURTLEFF 2011-10-20 US disclosed
US-20110118463-A1 METHOD FOR THE PRODUCTION OF 3,6-DIHYDRO-L, 3, 5-TRIAZINE DERIVATIVES FROM METFORMIN AND PARALDEHYDE DERIVATIVES POXEL SAS 2011-05-19 US disclosed
US-7169407-B1 Carbonyl stress-decreasing agent Miyata, Toshio (JP) 2007-01-30 US disclosed